PR Newswire 20-Jun-2017 4:01 PM
RICHMOND, Calif., June 20, 2017 /PRNewswire/ --Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by Sangamo. Sangamo intends to grant the underwriters a 30 day option to purchase up to 15% of the number of shares of common stock to be sold in the offering. Sangamo intends to use the proceeds from this offering for working capital and other general corporate purposes, including support for the continuing research and development of its genomic therapy product candidates and research programs, clinical trials, commercialization activities, business development activities and, if opportunities arise, acquisitions of businesses, products, technologies or licenses that are complementary to Sangamo's business.
Cowen and Company, LLC and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering.
A shelf registration statement on Form S-3 relating to the public offering of theshares of common stock described above was filed with the Securities and Exchange Commission (the "SEC") and is effective. A preliminary prospectus supplement relating to the offering has been filed with the SEC. Copies of the preliminary prospectus supplement and accompanying prospectus may be obtained, when available, from the offices of Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park Avenue, New York, New York 10152, or by telephone at (800) 326-5897 or email to firstname.lastname@example.org.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Forward Looking Statements
This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, the proposed public offering of shares of common stock and use of proceeds from the proposed offering. Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties relating to the completion of the public offering on the anticipated terms or at all, market conditions and the satisfaction of customary closing conditions related to the proposed offering. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. Additional risks and uncertainties relating to Sangamo and its business can be found under the heading "Risk Factors" in Sangamo's Registration Statement on Form S-3, as amended, initially filed with the SEC on May 26, 2017. Sangamo assumes no obligation to update the forward-looking information contained in this press release.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sangamo-therapeutics-announces-proposed-public-offering-of-common-stock-300476858.html
SOURCE Sangamo Therapeutics, Inc.